Yes, genetic polymorphisms, especially those affecting the CYP2D6 enzyme, can significantly influence tamoxifen's efficacy and toxicity profile. Patients with poor metabolizer status may experience reduced therapeutic benefits and altered toxicity profiles due to lower levels of active metabolites.
